India Pharma Outlook Team | Friday, 20 November 2026
Biopharma manufacturing in India is set to receive a major policy push as the Center prepares to roll out its Rs 10,000-crore Biopharma SHAKTI scheme by January 2027.
The Department of Pharmaceuticals is finalizing the policy for Cabinet consideration, with implementation planned over five years from FY2026-27 to FY2030-31.
The initiative aims to strengthen domestic production of biologics and biosimilars, support contract research, development and manufacturing organizations (CRDMOs), and expand clinical research infrastructure.
Its initial funding cycle is expected to prioritize projects addressing cancer, diabetes and autoimmune disorders, according to officials.
Also Read: How to Apply for India's Rs 10,000 Crore Biopharma SHAKTI Scheme
India has established a strong position in generic drug production, but expanding biopharmaceutical manufacturing requires specialized infrastructure, research capabilities and skilled professionals.
Biopharma SHAKTI aims to address these requirements by supporting CRDMOs and domestic biologics and biosimilars production. The initiative also includes a biopharma-focused research network and incentives for fermentation-based bulk drugs and building blocks.
The government plans to establish over 1,000 accredited clinical trial sites through the Indian clinical research network.
It will also create three new National Institutes of Pharmaceutical Education and Research (NIPERs) and upgrade seven existing institutes.
The Center also envisages strengthening the Central Drugs Standard Control Organization (CDSCO) through specialized scientific reviewers to improve regulatory evaluation of complex products.
The Rs 10,000-crore investment is intended to reduce import dependence and improve India's participation in the global biopharma market.
Stronger domestic research, manufacturing and clinical trial capabilities could support this transition.
However, the scheme's impact will depend on its final guidelines, funding allocation and implementation.